| scholarly article | Q13442814 |
| P50 | author | Richard Porter | Q90085980 |
| Peter Gallagher | Q56613319 | ||
| P2860 | cites work | Pituitary volume in psychosis | Q57403366 |
| The contribution of hypercortisolaemia to the cognitive decline of geriatric depression | Q58809521 | ||
| Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. | Q48495413 | ||
| Corticotropin-releasing factor binding sites in cortex of depressed suicides | Q48585998 | ||
| Memory disturbances and dexamethasone suppression test in major depression | Q48641168 | ||
| Psychiatric implications of basic and clinical studies with corticotropin-releasing factor | Q48679681 | ||
| Dehydroepiandrosterone treatment of midlife dysthymia | Q48759764 | ||
| Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls | Q48822983 | ||
| The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment | Q48823438 | ||
| Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study | Q48853473 | ||
| Cortical concentrations of corticotropin-releasing hormone and its receptor in Alzheimer type dementia and major depression | Q48889549 | ||
| The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness | Q49037226 | ||
| Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain | Q49052760 | ||
| Reduced cortisol latency in depressive illness | Q49112744 | ||
| Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression | Q49151158 | ||
| The age of dehydroepiandrosterone | Q49194178 | ||
| Age and sex related differences in serum levels of unconjugated dehydroepiandrosterone and its sulphate in normal subjects. | Q50943031 | ||
| Dissociation between pituitary and adrenal suppression to dexamethasone in depression. | Q51054966 | ||
| Effects of dexamethasone on neuroendocrine and psychological responses to L-tryptophan infusion. | Q51090395 | ||
| 5-Hydroxytryptamine receptor function in humans is reduced by acute administration of hydrocortisone. | Q51094049 | ||
| Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. | Q51574285 | ||
| Decreased memory performance in healthy humans induced by stress-level cortisol treatment. | Q51984207 | ||
| Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. | Q52050377 | ||
| Dose-dependent effects of hydrocortisone on memory in human males. | Q52142575 | ||
| A single administration of dehydroepiandrosterone does not enhance memory performance in young healthy adults, but immediately reduces cortisol levels. | Q52192302 | ||
| Cortisol suppression by dexamethasone in the healthy elderly: effects of age, dexamethasone levels, and cognitive function. | Q52371300 | ||
| Cortisol is secreted episodically by normal man. | Q54637115 | ||
| Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. | Q55063897 | ||
| Depression, Stress and the Adrenal axis | Q55895180 | ||
| The relevance of the in- versus outpatient status for studies on HPA-axis in depression: spontaneous hypercortisolism is a feature of major depressed inpatients and not of major depression per se. | Q48129129 | ||
| Similar age related increase of vasopressin colocalization in paraventricular corticotropin-releasing hormone neurons in controls and Alzheimer patients | Q48147230 | ||
| Neurosteroids, brain damage, and mental illness | Q48287980 | ||
| Neurocognitive impairment in drug-free patients with major depressive disorder | Q48377352 | ||
| In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients | Q48420025 | ||
| Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation | Q48433814 | ||
| Cortisol secretion in endogenous depression. II. Time-related functions | Q48456202 | ||
| Cortisol secretion in endogenous depression. I. Basal plasma levels | Q48456214 | ||
| Pituitary-adrenal axis rhythm disturbances in psychiatric depression. | Q48459415 | ||
| Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders | Q48459917 | ||
| Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor | Q22254872 | ||
| 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression | Q28142356 | ||
| Rapid reversal of psychotic depression using mifepristone | Q28191073 | ||
| DST studies in psychotic depression: a meta-analysis | Q28253516 | ||
| The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers | Q28373099 | ||
| Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin | Q29617507 | ||
| Gene regulation by steroid hormones | Q29618291 | ||
| Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone | Q30454280 | ||
| Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies | Q31043017 | ||
| The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety | Q33658043 | ||
| Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease | Q33885755 | ||
| Acute cortisone administration impairs retrieval of long-term declarative memory in humans | Q33895199 | ||
| Serotonin, stress and corticoids | Q33965272 | ||
| Future therapeutic targets in mood disorders: the glucocorticoid receptor | Q34074337 | ||
| Mineralocorticoid receptor function in major depression | Q34168296 | ||
| Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. | Q34174069 | ||
| Cytokines: abnormalities in major depression and implications for pharmacological treatment. | Q34339954 | ||
| Acute stress enhances memory for emotional words, but impairs memory for neutral words | Q34348639 | ||
| Treatment of depression with antiglucocorticoid drugs | Q34505235 | ||
| Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder | Q34547629 | ||
| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | Q35113118 | ||
| Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus | Q35541942 | ||
| Do antidepressants regulate how cortisol affects the brain? | Q35641579 | ||
| Corticosteroid-serotonin interactions in depression: a review of the human evidence. | Q35685169 | ||
| Cortisol and memory retrieval in humans: influence of emotional valence | Q36022735 | ||
| Glucocorticoid receptor function in vitro in patients with major depression | Q36194741 | ||
| Fortnighly review. Stress, the brain, and mental illness | Q36246017 | ||
| The glucocorticoid receptor: part of the solution or part of the problem? | Q36511702 | ||
| Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. | Q38428899 | ||
| Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. | Q38566515 | ||
| A molecular framework for the actions of glucocorticoid hormones in the nervous system | Q38769006 | ||
| Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment | Q39128639 | ||
| Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment | Q39412808 | ||
| The use of ketoconazole as an inhibitor of steroid production | Q39667196 | ||
| The Variations of Plasma Corticosterone/Cortisol Ratios Following ACTH Stimulation or Dexamethasone Administration in Normal Men | Q40099710 | ||
| Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis | Q40404354 | ||
| Glucocorticoids and the genesis of depressive illness. A psychobiological model | Q40577990 | ||
| The DST as a predictor of outcome in depression: a meta-analysis | Q40768542 | ||
| Phenotypic plasticity of CRF neurons during stress | Q40788429 | ||
| Neuronal birth and death | Q40790256 | ||
| Dehydroepiandrosterone protects hippocampal neurons against neurotoxin-induced cell death: mechanism of action | Q40918416 | ||
| Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs | Q40967879 | ||
| Biological heterogeneity of melancholia: results of pattern recognition methods | Q41131205 | ||
| Adrenocortical hyperactivity in depression: Effects of agitation, delusions, melancholia, and other illness variables | Q41286388 | ||
| Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims | Q41335204 | ||
| A corticosteroid/dopamine hypothesis for psychotic depression and related states | Q41339617 | ||
| Dexamethasone increases plasma free dopamine in man. | Q41436546 | ||
| Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility | Q41446274 | ||
| The validity of the dexamethasone suppression test as a marker for endogenous depression | Q41493075 | ||
| Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients | Q41561553 | ||
| Antiglucocorticoid treatment of depression: double-blind ketoconazole | Q41675968 | ||
| Neuropsychological impairment in bipolar disorder: the relationship with glucocorticoid receptor function | Q42164474 | ||
| Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications | Q42508360 | ||
| Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. | Q42514534 | ||
| Evidence against changes in corticotroph CRF receptors in depressed patients | Q42685827 | ||
| Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated | Q43504398 | ||
| Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects | Q43507948 | ||
| Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study | Q43620635 | ||
| Twenty-four-hour ACTH and cortisol pulsatility in depressed women | Q43653030 | ||
| Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine | Q43683161 | ||
| PET measurement of the influence of corticosteroids on serotonin-1A receptor number | Q43796246 | ||
| Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission | Q43873955 | ||
| Hypercortisolemic depression is associated with increased intra-abdominal fat. | Q43933213 | ||
| Effects of hydrocortisone administration on cognitive function in the elderly | Q43956690 | ||
| Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. | Q44045830 | ||
| The effects of sub-chronic administration of hydrocortisone on hormonal and psychological responses to L-tryptophan in normal male volunteers. | Q44107475 | ||
| Hypothalamic-pituitary-adrenal axis function in patients with chronic depression | Q44127479 | ||
| Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients | Q44228366 | ||
| Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression. | Q44464116 | ||
| Lack of effect of a single dose of hydrocortisone on serotonin(1A) receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635. | Q44628321 | ||
| Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy | Q44801155 | ||
| Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder | Q44917858 | ||
| A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. | Q45130108 | ||
| Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial | Q45176708 | ||
| Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression | Q45256266 | ||
| Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo | Q45256674 | ||
| Thyroid and adrenal axis in major depression: a controlled study in outpatients | Q45298859 | ||
| Pathways to the secretion of adrenocorticotropin: a view from the portal*. | Q46143786 | ||
| An open label trial of C-1073 (mifepristone) for psychotic major depression | Q46152690 | ||
| Cortisol circadian rhythm alterations in psychotic major depression | Q46508647 | ||
| Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders | Q46705432 | ||
| The perfect time to be stressed: a differential modulation of human memory by stress applied in the morning or in the afternoon | Q46757082 | ||
| Arousal and cortisol interact in modulating memory consolidation in healthy young men. | Q46955517 | ||
| Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression | Q46991276 | ||
| Pituitary size in depression | Q47433341 | ||
| Mood and neuropsychological function in depression: the role of corticosteroids and serotonin | Q47974513 | ||
| The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders | Q48101414 | ||
| The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness | Q48102324 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 193-209 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Acta Neuropsychiatrica | Q4676734 |
| P1476 | title | Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments | |
| P478 | volume | 18 |
| Q37901097 | A transdisciplinary perspective of chronic stress in relation to psychopathology throughout life span development. |
| Q24187372 | Antiglucocorticoid treatments for mood disorders |
| Q24242845 | Antiglucocorticoid treatments for mood disorders |
| Q40006472 | Association of glucocorticoid receptor polymorphisms with the susceptibility to major depressive disorder and treatment responses in Korean depressive patients |
| Q48428103 | Associations between hypothalamic-pituitary-adrenal axis function and facial emotion processing in depressed and control participants |
| Q38621902 | Autobiographical memory dysfunctions in depressive disorders. |
| Q28729989 | Can variation in hypothalamic-pituitary-adrenal (HPA)-axis activity explain the relationship between depression and cognition in bipolar patients? |
| Q22252261 | Cyclothymic disorder: A critical review |
| Q90527067 | Food Insecurity Is Associated With Poorer Mental Health and Sleep Outcomes in Young Adults |
| Q26863677 | Mechanisms underlying neurocognitive dysfunctions in recurrent major depression |
| Q34126352 | Processing of facial emotion expression in major depression: a review |
| Q28290605 | Treatment-resistant depression: critique of current approaches |
Search more.